You just read:

Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology

News provided by

Array BioPharma Inc.

Sep 13, 2018, 08:00 ET